http://rdf.ncbi.nlm.nih.gov/pubchem/patent/NZ-615738-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_81ad53b64eb74859acdc01278829b080 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-54 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-71 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57446 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2012-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66cc87061487cab00ae1de196919a322 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_78eec8aedb2d2d62f95bd9cb63f0b4f1 |
| publicationDate | 2015-11-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | NZ-615738-A |
| titleOfInvention | Methods for predicting and improving the survival of gastric cancer patients |
| abstract | Disclosed is a method for predicting the survival of a subject having stage I or II gastric cancer after tumor surgery, the method comprising: (a) determining the presence of activation or the level of activation of at least two analytes comprising cMET and HER1 in a cancer cell obtained from the subject, wherein cMET and HER1 are coactivated in the cancer cell; and (b) predicting the survival of the subject based upon the presence of activation or the level of activation of the at least two analytes determined in step (a), wherein the subject is predicted to have worse survival compared to stage I or II gastric cancer subjects with cMET activation in the absence of HER1 activation. Also disclosed is a of a cMET inhibitor and a HER1 inhibitor for the manufacture of a medicament for treating a subject having stage I or II gastric cancer, wherein cMET and HER1 are coactivated in the stage I or II gastric cancer, and wherein the subject has worse survival and/or poorer prognosis compared to stage I or II gastric cancer subjects with cMet activation in the absence of HER1 activation. |
| priorityDate | 2011-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1083.